In silico accelerated identification of structurally conserved CD8+ and CD4+ T-cell epitopes in high-risk HPV types

Infection, Genetics and Evolution

Volumn 12, Issue 7, 2012, Pages 1513-1518

  Gupta, Shishir K ^a   Srivastava, Mugdha ^b   Akhoon, Bashir A ^c   Gupta, Shailendra K ^c   Grabe, Niels ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Society for Biological Research and Rural Development   (India)

^c CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Cervical cancer; Epitope prediction; HPV; T cell epitopes

Indexed keywords

EPITOPE; VIRUS PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPUTER MODEL; GENE IDENTIFICATION; GENE STRUCTURE; GENETIC CONSERVATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; VACCINE PRODUCTION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLUSTER ANALYSIS; COMPUTER SIMULATION; CONSERVED SEQUENCE; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; MODELS, MOLECULAR; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84865370151     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2012.02.022     Document Type: Article

References (62)

1. Abagyan R.A., Batalov S. Do aligned sequences share the same fold?. J. Mol. Biol. 1997, 273:355-368.
2. Agorastos T., Chatzigeorgiou K., Brotherton M.L., Julia M.L., Garland S.M. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009, 27:7270-7281.
3. Akhoon B.A., Slathia P.S., Sharma P., Gupta S.K., Verma V. In silico identification of novel protective VSG antigens expressed by Trypanosoma brucei and an effort for designing a highly immunogenic DNA vaccine using IL-12 as adjuvant. Microb. Pathog. 2011, 51:77-87.
4. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997, 25:3389-3402.
5. Ashrafi G.H., Brown D.R., Fife K.H., Campo M.S. Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res. 2006, 120:208-211.
6. Baloria U., Akhoon B.A., Gupta S.K., Sharma S., Verma V. In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer. Amino Acids. 2011, 2011. 10.1007/s00726-010-0830-x.
7. Brusic V., August J.T. The changing field of vaccine development in the genomics era. Pharmacogenomics 2004, 5:597-600.
8. Brusic V., Rudy G., Harrison L.C. MHCPEP, a database of MHC-binding peptides: update 1997. Nucleic Acids Res. 1998, 26:368-371.
9. Bui H.H., Sidney J., Peters B., Sathiamurthy M., Sinichi A., Purton K.A., Mothé B.R., Chisari F.V., Watkins D.I., Sette A. Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics 2005, 57:304-314.
10. Chabot I., Goetghebeur M.M., Grégoire J.P. The societal value of universal child-hood vaccination. Vaccine 2004, 22:1992-2005.
11. 2: protein structure prediction server. Nucleic Acids Res. 2006, 34:W152-W157.
12. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996, 223:174-184.
13. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomavirus. Virology 2004, 324:17-27.
14. Dillner J., Dillner L., Utter G., Eklund C., Rotola A., Costa S., et al. Mapping of linear epitopes of human papillomavirus type 16: The L1 and L2 open reading frames. Int. J. Cancer 2006, 45:529-535.
15. Edgar R., Batzoglou S. Multiple sequence alignment. Curr. Opin. Struct. Bio. 2006, 16:368-373.
16. Eswar, N., Marti-Renom, M.A., Webb, B., Madhusudhan, M.S., Eramian, D., Shen, M.Y., Pieper, U., Sali, A., 2006. Comparative Protein Structure Modeling With MODELLER. Curr. Protoc. Bioinf. John Wiley & Sons, Inc., (Suppl. 15), 5.6.1-5.6.30.
17. Gunsteren, W.Fv, Billeter, S.R., Eising, A.A., Hünenberger, P.H., Krüger, P., Mark, A.E., Scott, W.R.P., Tironi, I.G., 1996. Biomolecular Simulations: The GROMOS96 Manual and User Guide: vdf Hochschulverlag AG an der ETHZ Zürich 1, 1-1042.
18. Gupta S.K., Singh A., Srivastava M., Gupta S.K., Akhoon B.A. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer. Vaccine 2010, 28:120-131.
19. Gupta S.K., Smita S., Sarangi A.N., Srivastava M., Akhoon B.A., Rahman Q., Gupta S.K. In silico CD4+ T-cell epitope prediction and HLA distribution analysis for the potential proteins of Neisseria meningitidis Serogroup B-a clue for vaccine development. Vaccine 2010, 28:7092-7097.
20. Gupta S.K., Srivastava M., Akhoon B.A., Smita S., Schmitz U., Wolkenhauer O., Vera J., Gupta S.K. Identification of immunogenic consensus T-cell epitopes in globally distributed influenza-A H1N1 neuraminidase. Infect. Genet. Evol. 2011, 2:308-319.
21. Han R., Reed C.A., Cladel N.M., Christensen N.D. Intramuscular injection of plasmid DNA encoding cottontail rabbit papillomavirus E1, E2, E6 and E7 induces T-cell-mediated but not humoral immune responses in rabbits. Vaccine 1999, 17:1558-1566.
22. Hitzeroth I.I., Passmore J.A.S., Shephard E., Stewart D., Müllerd M., Williamson A.L. Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine 2009, 27:6432-6434.
23. Hung C.F., Monie A., Alvarez R.D., Wu T.C. DNA vaccines for cervical cancer: from bench to bedside. Exp. Mol. Med. 2007, 39:679-689.
24. Illergård K., Ardell D.H., Elofsson A. Structure is three to ten times more conserved than sequence - A study of structural response in protein cores. Proteins: Struct., Funct., Bioinf. 2009, 77:499-508.
25. Kabsch W. A solution for the best rotation to relate two sets of vectors. Acta Crystallogr. 1976, 32:922-923.
26. Kabsch W. A discussion of the solution for the best rotation to relate two sets of vectors. Acta Crystallogr. 1978, 34:827-828.
27. Kaplan W., Littlejohn T.G. Swiss-PDB Viewer [Deep View]. Brief. Bioinform. 2001, 2:195-197.
28. Kim D., Garnbhira R., Karanam B., Monie A., Hung C.F., Roden R., et al. Generation and characterization of a preventative and therapeutic HPV DNA vaccine. Vaccine 2008, 26:351-360.
29. Kanodia S., Fahey L.M., Kast W.M. Mechanisms used by human papillomaviruses to escape the host immune response. Curr. Cancer Drug Targets 2007, 7:79-89.
30. La Torre G., de Waure C., Chiaradia G., Mannocci A., Ricciardi W. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 2007, 25:8352-8358.
31. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
32. Lin K., Doolan K., Hung C.F., Wu T.C. Perspectives for Preventive and Therapeutic HPV Vaccines. J. Formos. Med. Assoc. 2010, 109:4-24.
33. Madden D.R. The three-dimensional structure of peptide-MHC complexes. Annu. Rev. Immunol. 1995, 13:587-622.
34. Maenaka K., Jones E.Y. MHC superfamily structure and the immune system. Curr. Opin. Struct. Biol. 1999, 9:745-753.
35. Meijer C.J.L.M., Heideman A.M.D., Berkhof H., Snijders J.F.P. Prevention of cervical cancer: where immunology meets diagnostics. Immunol. Lett. 2009, 122:126-127.
36. Meng E.C., Pettersen E.F., Couch G.S., Huang C.C., Ferrin T.E. Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinf. 2006, 7:339.
37. Miura S., Kawana K., Schust D.J., Fujii T., Yokoyama T., Iwasawa Y., et al. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J. Virol. 2010, 84:11614-11623.
38. Muňoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., Snijders P.J., Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348:518-527.
39. Nielsen M., Lundegaard C., Worning P., Lauemøller S.L., Lamberth K., Buus S., Brunak S., Lund O. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protoc. Sci. 2003, 12:1007-1017.
40. Ortiz A.R., Strauss C.E., Olmea O. MAMMOTH [matching molecular models obtained from theory]: an automated method for model comparison. Protein Sci. 2002, 11:2606-2621.
41. Ovsyannikova I.G., Jacobson R.M., Poland G.A. Variation in vaccine response in normal populations. Pharmacogenomics 2004, 5:417-427.
42. Peters B., Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinf. 2005, 6:132.
43. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF chimera-a visualization system for exploratory research and analysis. J. Comp. Chem. 2004, 25:1605-1612.
44. Reche P.A., Reinherz E.L. Sequence variability analysis of human class I and class II MHC molecules: functional and structural correlates of amino acid polymorphisms. J. Mol. Biol. 2003, 331:623-641.
45. Ruutu M., Frazer I.H., Liu X. Therapeutic vaccination against cervical cancer are we near?. Cancer Forum. 2008, 32:98-103.
46. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. The Lancet 2007, 370:890-907.
47. Sette A., Fikesy J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 2003, 15:461-470.
48. Sette A., Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999, 50:201-212.
49. Shannon, C.E., 1948. The mathematical theory of communication. Bell. Syst. Tech. J. 27, 379-423 and 623-656.
50. Shortle D., Simons K.T., Baker D. Clustering of low-energy conformations near the native structures of small proteins. Proc. Natl. Acad. Sci. 1998, 95:11158-11162.
51. Siew N., Elofsson A., Rychlewski L., Fischer D. MaxSub: an automated measure for the assessment of protein structure prediction quality. Bioinformatics 2000, 16:776-785.
52. Sinigaglia F., Hammer J. Motifs and supermotifs for MHC class II binding peptides. J. Exp. Med. 1995, 181:449-451.
53. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., Clifford G.M. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer. 2007, 121:621-632.
54. Srivastava M., Gupta S.K., Abhilash P.C., Singh N. Structure prediction and binding sites analysis of curcin protein of Jatropha curcas using computational approaches. J. Mol. Model. 2011, 10.1007/s00894-011-1320-0.
55. Steele J.C., Stankovic T., Gallimore P.H. Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein. J. Virol. 1993, 67:2799-2806.
56. Stern L.J., Wiley D.C. Antigen peptide binding by class I and class II histocompatibility proteins. Structure 1994, 2:245-251.
57. Tung C.W., Ho S.Y. POPI: predicting immunogenicity of MHC class I binding peptides by mining informative physicochemical properties. Bioinformatics 2007, 23:942-949.
58. Wain G. The human papillomavirus (HPV) vaccine, HPV related diseases and cervical cancer in the post-reproductive years. Maturitas 2010, 65:205-209.
59. Wang J.H., Reinherz E. Structural basis of T-cell recognition of peptides bound to MHC molecules. Mol. Immunol. 2001, 38:1039-1049.
60. Whisstock J.C., Lesk A.M. Prediction of protein function from protein sequence and structure. Q. Res. Biophys. 2003, 36:307-340.
61. Zhang Q., Wang P., Kim Y., Andersen P.H., Beaver J., Bourne P.E., Bui H.H., Buus S., Frankild S., Greenbaum J., Lund O., Lundegaard C., Nielsen M., Ponomarenko J., Sette A., Zhu Z., Peters B. Immune epitope database analysis resource [IEDB-AR]. Nucleic Acids Res. 2008, 36:513-518.
62. Zhang Y., Skolnick J. The protein structure prediction problem could be solved using the current PDB library. Proc. Natl. Acad. Sci. 2005, 102:1029-1034.